Strong rebound of wakefulness follows prostaglandin D-2- or adenosine A(2a) receptor agonist-induced sleep

Citation
D. Gerashchenko et al., Strong rebound of wakefulness follows prostaglandin D-2- or adenosine A(2a) receptor agonist-induced sleep, J SLEEP RES, 9(1), 2000, pp. 81-87
Citations number
26
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Neurosciences & Behavoir
Journal title
JOURNAL OF SLEEP RESEARCH
ISSN journal
0962-1105 → ACNP
Volume
9
Issue
1
Year of publication
2000
Pages
81 - 87
Database
ISI
SICI code
0962-1105(200003)9:1<81:SROWFP>2.0.ZU;2-Z
Abstract
We studied the effect of sleep excess on the sleep-wakefulness pattern of r ats. Subarachnoid infusion of prostaglandin D-2 or the adenosine A(2a) rece ptor agonist CGS21680 effectively induced slow wave sleep (SWS) for the fir st 12 h of the night-time period, whereas they did not induce sleep during the following 24 h of infusion. An increase in the amount of wakefulness wa s seen during the last 12 h of prostaglandin D-2 infusion. The amounts of w akefulness strongly increased during the following 36-h recovery period. Re bound wakefulness was extraordinarily strong after the cessation of CGS2168 0 infusion, reaching almost complete insomnia during the night-time. Treatm ent of animals with prostaglandin D-2 overnight, following by treatment wit h CGS21680 on the next night, resulted in the strongest induction of wakefu lness rebound. During the rebound period, the amount of wakefulness reached up to 50 min per hour in the daytime. Rebound of wakefulness depended on t he amounts of preceding SWS induced by infusion of prostaglandin D-2 for 6 or 12 h and of CGS21680 for 12 h. The larger the amount of SWS, the larger the amount of the following rebound of wakefulness. Rebounds of wakefulness occurred as a result of decrease in SWS amounts, whereas paradoxical sleep amounts did not change. Desensitization of adenosine A(2a) receptors and a ccumulation of prostaglandin E-2 may be involved in the production of stron g wakefulness rebound following relatively long treatments (more than 12 h) with prostaglandin D-2 or CGS21680.